1231930-29-2

Basic information

• Product Name: EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)-
• Synonyms: EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)-;N-(4-bromo-2,6-difluoro-phenyl)-N'-isopropyl-acetamidine;N-(4-Bromo-2,6-difluorophenyl)-N'-(1-Methylethyl)-ethanimidamide
• CAS NO: 1231930-29-2
• Molecular Formula: C₁₁H₁₃BrF₂N₂
• Molecular Weight: 291.1351264
• Mol File: 1231930-29-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 354.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• PKA: 6.53±0.50(Predicted)
• CAS DataBase Reference: EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)-(1231930-29-2)
• EPA Substance Registry System: EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)-(1231930-29-2)

Safety Data

• Hazardous Substances Data: 1231930-29-2(Hazardous Substances Data)

Usage

General Description

EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)- is a chemical compound used as a sedative-hypnotic medication. It acts on the central nervous system to produce a calming effect, making it useful for treating anxiety and insomnia. EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)- is a derivative of the sedative-hypnotic drug, midazolam, and is sometimes used in combination with other medications for anesthesia. It is classified as a benzodiazepine, a class of drugs known for their sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxant properties. However, it is important to use this compound under the supervision of a healthcare professional, as it can be habit-forming and may cause side effects such as drowsiness, dizziness, and impaired coordination.

Upstream product

• 1118-69-0 N-isopropylacetamide 
• 67567-26-4 4-bromo-2,6-difluoroaniline 

Downstream Products

• 1231930-33-8 6-bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole 
• 1231930-82-7 abemaciclib 
• 1231930-42-9 6-(2-chloro-5-fluoropyrimidin-4-yl)-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole 
• 1231930-37-2 4-fluoro-1-isopropyl-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1H-benzo[d]imidazole 
• 1231929-97-7 N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)-2-pyrimidinamine 

Relevant articles and documents

COMBINATION THERAPY FOR CANCER

The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising: [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H- benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-VEGFR2 antibody, preferably, ramucirumab.